Trials Sponsors Conditions Drugs Pricing

Conditions

Obesity or Overweight Weight-Related Comorbidity with/without Diabetes Mellitus, Type 2 Obesity or Overweight Weight-Related Comorbidity With/Without Diabetes Mellitus, Type 2

Keywords

ObesityOverweightAZD6234LenbelintideDiabetes Mellitus, Type 2

Outcome Measures

Primary Outcomes (1)

Percent change in body weight from baseline at 68 weeks of treatment
To evaluate the effect of AZD6234 as compared to placebo as an adjunct to incretin-based therapies in percent body weight change
68 weeks

Secondary Outcomes (8)

Percent change in body weight from baseline at 68 weeks of treatment
68 weeks
Absolute change in weight (kg) from baseline at 68 weeks of treatment
68 weeks

Study Arms (2)

AZD6234

EXPERIMENTAL

AZD6234

Drug: Lenbelintide

Placebo

PLACEBO COMPARATOR

Matching placebo

Drug: Placebo

Interventions

LenbelintideDrug

IMP injected subcutaneously, once a week.

Also known as: AZD6234

AZD6234

PlaceboDrug

Placebo matching IMP dose injected subcutaneously, once a week.

Placebo

Eligibility Criteria

Age18 Years+

Sexall

Healthy VolunteersNo

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Males \& females (inclusive of all gender identities) age ≥18 years
BMI ≥ 30 kg/m2 OR BMI ≥ 27 kg/m2 with at least one of the following weight-related comorbidities (treated or untreated): hypertension, dyslipidaemia, obstructive sleep apnoea, cardiovascular disease, heart failure, chronic kidney disease, metabolic dysfunction associated steatotic liver disease, osteoarthritis of the knee, or stress urinary incontinence

Sponsors & Collaborators

AstraZeneca AB
Industrylead
AstraZeneca
Industrylead

Study Sites (96)

Research Site

Escondido, California, 92025, United States

NOT_YET_RECRUITING

Research Site

Lincoln, California, 95648, United States

RECRUITING

Research Site

Walnut Creek, California, 94598, United States

NOT_YET_RECRUITING

Research Site

Jacksonville, Florida, 32204, United States

MeSH Terms

Conditions

ObesityOverweightDiabetes Mellitus, Type 2

Condition Hierarchy (Ancestors)

OvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System Diseases

Central Study Contacts

AstraZeneca Clinical Study Information Center

CONTACT

1-877-240-9479 information.center@astrazeneca.com

Study Design

Study Type: interventional
Phase: phase 3
Allocation: RANDOMIZED
Masking: QUADRUPLE
Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose: TREATMENT
Intervention Model: PARALLEL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

August 10, 2026

First Posted

August 20, 2026

Study Start

August 24, 2026

Actual (reported)

Primary Completion

A Study to Evaluate Effect of AZD6234 as an Adjunct to Incretin-based Therapies in Adult Participants With Obesity or Overweight With Weight-related Comorbidity With or Without Type 2 Diabetes Mellitus

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

AZD6234

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (96)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

First Submitted

First Posted

Study Start

Primary Completion

Study Completion

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Secondary Outcomes (8)

Study Arms (2)

AZD6234

Placebo

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (96)

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Central Study Contacts

Study Design

Study Record Dates

You may not qualify if:

Data Sharing

Source records

Locations